Physician profile
Jay D Smith
NPI 1316930944
$14,352.07
in general payments reported to CMS, 2019-2025
46 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $1,411 · 2021: $1,993 · 2022: $2,145 · 2023: $1,931 · 2024: $2,430 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,694.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,336.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,567.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $1,110.04 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,011.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $842.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.69 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $571.58 | 2019-2025 | Steglatro, Belsomra, Capvaxive |
| Abbvie INC. | $544.86 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Abbott Laboratories | $525.90 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $524.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $473.51 | 2022-2025 | |
| Amarin Pharma, INC. | $353.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.16 | 2019-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $255.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $143.82 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.